Starting from small molecule mTOR inhibitor Torin1, replacement of the piperazine ring with a phenyl ring resulted in a new series of mTOR inhibitors (as exemplified by 10) that showed superior potency and selectivity for mTOR, along with significantly improved mouse liver microsome stability and a longer in vivo half-life.
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Mammalian target of rapamycin (mTOR) is a key node of the PI3K/Akt/mTOR signal transduction pathway. mTOR pathway has been found to be deregulated in a variety of cancers and has been extensively studied as an oncology drug discovery target. [1] [2] [3] [4] Upon activation by external or internal stimuli such as growth factors, nutrients, stress, and energy, mTOR regulates cell growth, proliferation, metabolism, and autophagy through the mTORC1 and mTORC2 complexes by phosphorylation of downstream targets S6K, 4EBP1, and Akt. 5 The successful clinical application of rapamycin in renal cell carcinoma has validated mTOR as an anti-cancer drug discovery target. However, a lack of activity against mTORC2, incomplete inhibition of mTORC1 function and negative reactivation of Akt through the S6K/IRS1 pathway may explain the limited clinical efficacy observed with rapamycin related compounds (rapalogs). [6] [7] [8] Currently, there is significant interest in the development and characterization of ATP-competitive mTOR inhibitors, which would result in complete inhibition of both mTORC1 and mTORC2. mTOR is a member of the PI3K kinase family, which consists of the PI3Ks, DNA-PK, ATR, ATM, and SMG-1.
9 PI3Ks, especially PI3Ka, have been found to be hyperactivated in a wide spectrum of cancers, and are currently being evaluated as an anti-cancer drug target in the clinic. 1 The structural similarity between PI3Ks and mTOR endowed many early PI3K or mTOR inhibitors, like PI-103 and BEZ-235, with dual activity against both targets. 10,11 Because
PI3Ks are upstream regulators of Akt, a central hub of many critical cellular processes, it is believed that mTOR-selective inhibitors may demonstrate improved toxicology relative to dual PI3K/mTOR inhibitors. Many of the recently disclosed mTOR inhibitors, including Torin1, have demonstrated that it is possible to selectively inhibit mTOR versus PI3Ks.
12-22
We recently prepared a series of tricyclic benzonaphthyridinones, exemplified by Torin1, as highly potent and selective mTOR inhibitors. Torin1 has more than 800-fold selectivity for mTOR relative to PI3Ks in cellular assays and has no other significant protein kinase off-targets among the 450 kinases profiled by KINOMEscan TM . 12 Torin1 exhibited anti-tumor activity in a U87-MG mouse xenograft that correlated with target inhibition. However, Torin1 exhibits poor mouse microsome stability and a short in vivo halflife which limit its utility as a pharmacological agent in vivo. In this Letter, we describe our efforts to improve the pharmacokinetic properties of Torin1 by replacing the metabolically labile phenylpiperazine moiety with a biphenyl system to yield compounds such as 10 ( Fig. 1) .
The preparation of compound 10 and analogs is illustrated in Scheme 1. Ethyl-4,6-dichloroquinoline-3-carboxylate (1) jected to nucleophilic substitution with 4-bromo-3-trifluoromethaneaniline (2) to afford compound 3. Reduction of ethyl ester 3 with NaBH 4 generated benzyl alcohol 4, which was subjected to benzylic oxidation with MnO 2 and olefination/cyclization in situ to furnish general intermediate 5. Pinacol boronic ester 6 was obtained from 4-bromo-benzonic acid (8) via Suzuki coupling and amide formation. A bromine-selective Suzuki coupling was used to install the benzoate side chain (or other substituent in the analogs) to afford the intermediate 7. Finally, the quinoline side chain (or other substituent in the analogs) was attached at the chlorine position using more vigorous Suzuki coupling conditions to afford the final product illustrated by compound 10.
Following this general synthetic strategy, a focused library of compounds was generated by varying the benzoate side chain, quinoline side chain and CF 3 /CH 3 moiety. The selected compounds were evaluated in parallel in biochemical assays with mTORC1 complex in cellular assays using a mouse embryonic fibroblast (MEF) cell line by examining the phosphorylation status of mTOR downstream targets such as S6K (T389), and for PI3K activity with the Akt S473D PC-3 cell line by examining the phosphorylation status of AktT308. The results are summarized in Table 1 .
Based on the Torin1 series, we first retained the quinoline moiety at the R 1 position, which was presumably responsible for the selectivity and potency against mTOR. Replacing the phenylpiperazine ring with a biphenyl system provided compounds that demonstrated excellent potency against mTOR and selectivity relative to PI3K. Methyl amide 11, THP-protected benzyl alcohol 12, benzyl alcohol 13, carboxylic acid 14, and primary amide 16 all demonstrated the same level of potency against mTOR (EC 50 values between 15-30 nM) and the same selectivity over PI3K (EC 50 over 300 nM). The methyl ester 15 lost a significant amount of activity against mTOR, suggesting that the active members of this series of compounds possess hydrogen bond donors through either an -OH, -COOH or -CONH 2 functionality. N-methyl-piperidin-4-amine amide 10 exhibited the best potency against mTOR (EC 50 = 5 nM, the same as Torin1) and 200-fold selectivity over PI3K. The compounds derived from replacing the quinoline moiety with aminopyrimidine (17) or pyrazole (18) systems were slightly less potent against mTOR, indicating that the inner hydrophobic pocket required a larger substituent. In order to reduce the molecular weight and obtain better solubility, while the R 2 fragment was kept as methyl-piperidin-4-amine, the CF 3 group was replaced with a CH 3 group and the R 1 side chain was varied to include a pyrazole (20) , methylpyrazole (21), 7-azaindole (22), hydrogen (23) and aminopyridine (24). However, all of these analogs failed to produce the same level of potency against mTOR, although the selectivity over PI3Ks was retained. Compound 19, which bears quinoline side chain at the R 1 position, retained the same potency and selectivity against mTOR as Torin1 and compound 10. This reaffirmed that quinoline was the best side chain to occupy the inner hydrophobic pocket, and that the hydrogen bond provided by the -OH or -NH 2 was critical to maintain potency. With the best activity and selectivity, compounds 10 and 19 were chosen for mouse stability study, single point CYP450 inhibition test Scheme 1. Reagents and conditions: (a) 1,4-dioxane, 85°C, 4 h, 80% yield; (b) NaBH 4 , EtOH, rt, 4 h, 50% yield; (c) MnO 2 , CH 2 Cl 2 , rt, 2 h, then triethylphosphonoacetate, K 2 CO 3 , EtOH, 100°C, 12 h, 60% yield; (d) 6, PdCl 2 (Ph 3 P) 2 , Na 2 CO 3 , 1,4-dioxane, 80°C, 2 h, 60% yield; (e) quinoline-3-boronic acid, PdCl 2 (Ph 3 P) 2 , t-Bu-Xphos, Na 2 CO 3 , 1,4-dioxane, 100°C, 4 h, 50% yield; (f) PdCl 2 (dppf), bis(pinacolato)diboron, KOAc, 1,4-dioxane, 80°C, 12 h; crude material was used without purification; (g) HATU, THF, 1-methylpiperidin-4-amine, diisopropylethylamine, rt, 50% over two steps. (Table 2) , and in vivo mouse pharmacokinetic analysis (Table 3) . In comparison to Torin1, compounds 10 and 19 demonstrated significant improvements in stability in the mouse microsome assay (46 and 42 min, respectively), where both were subjected to NADPHdependent metabolism. In the single point CYP450 metabolic enzyme inhibitory assay, compound 10 showed more than 60% and 50% inhibition at 10 lM against the major metabolic enzymes CYP3A4 and CYP2D6, respectively, while compound 19 demonstrated weaker inhibition (34% and 24%, respectively). Further investigations of the ability of these compounds to inhibit metabolism are warranted prior to performing combination studies. The improved microsome stability profile of compounds 10 and 19 encouraged us to evaluate their in vivo pharmacokinetic properties. Upon intravenous (7.5% NMP and 40% PEG400 in water) and oral (0.1% v/v Tween-80, 0.5% w/v NaCMC in water) administration, compound 10 demonstrated superior pharmacokinetic properties relative to compound 19, although both were significantly better than Torin1. 12 The half-life was improved to 3.6 h (10) and 1.8 h (19) from that of Torin1 (0.5 h). The bioavailability of compound 10 (10.1%) was double that of Torin1 (5.5%), while the bioavailability of compound 19 was 5.4%. Compound 10 also demonstrated much better exposure using both IV and PO delivery routes compared to Torin1 (1388/1411 vs 720/396 hrÃng/mL).
Other pharmacokinetic properties such as clearance rate (11.9 vs 23.0 mL/min/Kg) and volume of distribution (1.95 vs 0.59 L/Kg)
were also superior to those of Torin1. The slower T max of compound 10 (4 h) compared to compound 19 (1 h) and Torin1 (0.5 h) was indicative of poor solubility and/or slow absorption.
To evaluate the kinase selectivity of compound 10, it was subjected to the Ambit kinome-wide screen using KINOMEscan TM technology. The assay showed that compound 10 was very selective and did not strongly hit any other protein kinases among the 353 kianses tested, except for several PI3K family lipid kinases (Table 4) .
Compound 10 was evaluated in an in vivo pharmacodynamic study, where it exhibited significant inhibitory activity against the downstream targets of mTOR, S6K, and Akt, and blocked 80-90% phosphorylation of S6K (T389) and pAkt (S473) in liver and lung tissues even after 6 h at a dosage of 20 mg/kg. In summary, starting from Torin1, replacement of the metabolically labile 4-amino-phenylpiperazine moiety with a biphenyl system provided a new series of inhibitors that were exemplified by compound 10, which demonstrated significant improvements in mouse microsome stability and in vivo pharmacokinetic properties. Compound 10 is a potent and selective mTOR inhibitor suitable for use in cell culture and in vivo. Further elaboration of this a IC 50 determinations are the mean of two of independent measurements with a standard error of <20%.
scaffold class to improve the drug-like properties will be reported in due course.
